BITE and DLI

Phase 2Small molecule

FFirst Affiliated Hospital of Zhejiang University

BITE and DLI is one of 42 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoblastic LeukemiaRecruiting

Acute Lymphoblastic LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

148 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

39 2

Oncovin

Eli Lilly

Phase 3

73 3

Oncaspar

SServier

Phase 3

47 4

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

40 5

Elspar

DDutch Childhood Oncology Group

Phase 3

44 6

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

42 7

Fludara

Sanofi

Phase 3

15 8

Cellcept

Roche

Phase 3

11 9

Iclusig

Neoral

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Acute Lymphoblastic Leukemia

NCT07105579

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT07105579·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BITE and DLI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BITE and DLI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BITE and DLI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFirst Affiliated Hospital of Zhejiang University

BITE and DLI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News